We aimed to assess the impact of treatment with etoricoxib or diclofenac on risk of CHF relative to baseline risk factors. Conclusion: History of CHF was highly associated with risk for CHF ...

Rockville, MD - The US FDA has deemed that the new selective COX-2 inhibitor etoricoxib (Arcoxia, Merck & Co) is "approvable" but that additional data on safety and efficacy are required before ...